Тhe role of fenofibrate (tricor) in the complex treatment of microangiopathic complications in patients with type 2 diabetes

Najmutdinova D.Q., Parpibaeva D.A.,Salaeva M.S.,Salimova N.D.,Ergashov N.Sh.,Sultonova D.A.

dc.contributor.author	Najmutdinova D.Q., Parpibaeva D.A.,Salaeva M.S.,Salimova N.D.,Ergashov N.Sh.,Sultonova D.A.
dc.date.accessioned	2023-03-02T10:01:38Z
dc.date.available	2023-03-02T10:01:38Z
dc.date.issued	2023-02
dc.identifier.issn	2949-7701
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/6569
dc.description.abstract	The results of numerous studies convincingly prove that fenofibrate, by affecting the activity of PPAR receptors, has hypolipidemic, antiinflammatory and antioxidant effects. Activation of PPAR receptors in the liver leads to a decrease in the level of lipids that cause atherosclerosis (VLDL, small dense LDL), and an increase in the level of antiatherogenic HDL. Activation of PPAR-α in vascular cells allows to reduce the activity of inflammatory markers, such as C-reactive protein, tumor necrosis factor-β, interleukin-6, fibrinogen, etc. These advantages ultimately reduce the risk of development and progression of macro- and microvascular complications in diabetes mellitus.This abstract will review Evidence-based summary of the efficacy of fenofibrate (Tricor) in the complex treatment of microangiopathic complications in patients with type 2 diabetes.	en_US
dc.language.iso	en_US	en_US
dc.publisher	Neo Science Peer Reviewed Journal	en_US
dc.subject	Diabetes mellitus, FIELD, ACCORD-eye, Diabetic microangiopathy, dyslipidemia, fenofibrate (tricor)	en_US
dc.title	Тhe role of fenofibrate (tricor) in the complex treatment of microangiopathic complications in patients with type 2 diabetes	en_US
dc.type	Article	en_US